Effects of osteoprotegerin/TNFRSF11B in two models of abdominal aortic aneurysms

Vorkapic,Emina; Kunath,Anne; Wågsäter,Dick

doi:10.3892/mmr.2018.8936

Effects of osteoprotegerin/TNFRSF11B in two models of abdominal aortic aneurysms

Authors:
- Emina Vorkapic
- Anne Kunath
- Dick Wågsäter
View Affiliations

Affiliations: Division of Drug Research, Department of Medical and Health Sciences, Linköping University, 581 85 Linköping, Sweden
Published online on: April 27, 2018 https://doi.org/10.3892/mmr.2018.8936
Pages: 41-48
Copyright: © Vorkapic et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteoprotegerin (OPG), additionally termed tumor necrosis factor receptor superfamily member 11B, is produced by vascular smooth muscle cells (VSMCs) and endothelial cells in the vasculature, and its release may be modulated by pro‑inflammatory cytokines, including interleukin‑1β and tumor necrosis factor‑α. The present study investigated the effects of treatment with low‑dose human recombinant OPG on abdominal aortic aneurysm (AAA) development in mice. Mice were treated with 1 µg human recombinant OPG four times (or vehicle) for 2 weeks prior to inducing AAA. A total of two different models for inducing AAA were used to investigate the hypothesis as to whether OPG is involved in key events of AAA development, using osmotic mini‑pumps with angiotensin II in apolipoprotein‑E (ApoE‑/‑) mice for 28 days or using periaortic application of CaCl2 on the aorta in C57Bl/6J mice for 14 days. OPG was continuously administered during the experimental period. Histological staining using Masson's trichrome, Verhoeff's van‑Gieson and picro‑sirius red, in addition to reverse transcription‑quantitative polymerase chain reaction analysis of various markers, were used to analyze phenotypic alterations. Treatment with OPG had no inhibitory effect on AAA development in the angiotensin II model in ApoE‑/‑ mice, which developed suprarenal aneurysms, although it increased vessel wall thickness of the aorta and total collagen in C57Bl/6J mice using the CaCl2 model that induced infrarenal dilation of the aorta. Treatment with OPG did not inhibit aneurysm development and key events, including inflammation, extracellular matrix or VSMC remodeling, in aortas from OPG‑treated mice with periaortic treatment with CaCl2. The results indicated that mice treated with low levels of human recombinant OPG may have a more stable aneurysmal phenotype due to compensatory production of collagen and increased vessel wall thickness of the aorta, potentially protecting the aneurysm from rupture. Further studies investigating rupture models of AAA in addition to using higher levels of OPG are require to verify this speculation. Furthermore, treatment with low levels of OPG in patients with AAA may represent a novel therapeutic strategy for the treatment of AAA as well as attenuate the adverse effects associated with the administration of normal and high dosages of OPG.

View Figures

View References

1	Assar AN and Zarins CK: Ruptured abdominal aortic aneurysm: A surgical emergency with many clinical presentations. Postgrad Med J. 85:268–273. 2009. View Article : Google Scholar : PubMed/NCBI
2	Toghill BJ, Saratzis A and Bown MJ: Abdominal aortic aneurysm-an independent disease to atherosclerosis? Cardiovasc Pathol. 27:71–75. 2017. View Article : Google Scholar : PubMed/NCBI
3	Shimizu K, Libby P and Mitchell RN: Local cytokine environments drive aneurysm formation in allografted aortas. Trends Cardiovasc Med. 15:142–148. 2005. View Article : Google Scholar : PubMed/NCBI
4	Moran CS, McCann M, Karan M, Norman P, Ketheesan N and Golledge J: Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation. 111:3119–3125. 2005. View Article : Google Scholar : PubMed/NCBI
5	Moran CS, Clancy P, Biros E, Blanco-Martin B, McCaskie P, Palmer LJ, Coomans D, Norman PE and Golledge J: Association of PPARgamma allelic variation, osteoprotegerin and abdominal aortic aneurysm. Clin Endocrinol (Oxf). 72:128–132. 2010. View Article : Google Scholar : PubMed/NCBI
6	Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, et al: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 273:14363–14367. 1998. View Article : Google Scholar : PubMed/NCBI
7	Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, et al: Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell. 89:309–319. 1997. View Article : Google Scholar : PubMed/NCBI
8	Pan G: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 277:815–818. 1997. View Article : Google Scholar : PubMed/NCBI
9	de Ciriza Pérez C, Lawrie A and Varo N: Osteoprotegerin in cardiometabolic disorders. Int J Endocrinol. 2015:5649342015.PubMed/NCBI
10	Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:165–176. 1998. View Article : Google Scholar : PubMed/NCBI
11	Hofbauer LC and Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 292:490–495. 2004. View Article : Google Scholar : PubMed/NCBI
12	Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, et al: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 397:315–323. 1999. View Article : Google Scholar : PubMed/NCBI
13	Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O'Brien T and Khosla S: Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun. 280:334–339. 2001. View Article : Google Scholar : PubMed/NCBI
14	Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, Keaney JF Jr, Rong J, Corey D, Hoffmann U, Fox CS, et al: Biomarkers of the osteoprotegerin pathway: Clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol. 30:1849–1854. 2010. View Article : Google Scholar : PubMed/NCBI
15	Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, Jain T, Gruntmanis U, McGuire DK and de Lemos JA: Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol. 99:513–518. 2007. View Article : Google Scholar : PubMed/NCBI
16	Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W and Willeit J: Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 109:2175–2180. 2004. View Article : Google Scholar : PubMed/NCBI
17	Koole D, Hurks R, Schoneveld A, Vink A, Golledge J, Moran CS, de Kleijn DP, van Herwaarden JA, de Vries JP, Laman JD, et al: Osteoprotegerin is associated with aneurysm diameter and proteolysis in abdominal aortic aneurysm disease. Arterioscler Thromb Vasc Biol. 32:1497–1504. 2012. View Article : Google Scholar : PubMed/NCBI
18	Schoppet M, Preissner KT and Hofbauer LC: RANK ligand and osteoprotegerin: Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 22:549–553. 2002. View Article : Google Scholar : PubMed/NCBI
19	Collin-Osdoby P: Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 95:1046–1057. 2004. View Article : Google Scholar : PubMed/NCBI
20	Venuraju SM, Yerramasu A, Corder R and Lahiri A: Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol. 55:2049–2061. 2010. View Article : Google Scholar : PubMed/NCBI
21	Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, Schwartz SM, Giachelli CM and Rosenfeld ME: Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol. 26:2117–2124. 2006. View Article : Google Scholar : PubMed/NCBI
22	Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, et al: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:1260–1268. 1998. View Article : Google Scholar : PubMed/NCBI
23	Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, et al: Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 192:463–474. 2000. View Article : Google Scholar : PubMed/NCBI
24	Ovchinnikova O, Gylfe A, Bailey L, Nordström A, Rudling M, Jung C, Bergström S, Waldenström A, Hansson GK and Nordström P: Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice-brief report. Arterioscler Thromb Vasc Biol. 29:1478–1480. 2009. View Article : Google Scholar : PubMed/NCBI
25	Candido R, Toffoli B, Corallini F, Bernardi S, Zella D, Voltan R, Grill V, Celeghini C and Fabris B: Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J Vasc Res. 47:252–261. 2010. View Article : Google Scholar : PubMed/NCBI
26	Moran CS, Jose RJ, Biros E and Golledge J: Osteoprotegerin deficiency limits angiotensin II-induced aortic dilatation and rupture in the apolipoprotein E-knockout mouse. Arterioscler Thromb Vasc Biol. 34:2609–2616. 2014. View Article : Google Scholar : PubMed/NCBI
27	Bumdelger B, Kokubo H, Kamata R, Fujii M, Yoshimura K, Aoki H, Orita Y, Ishida T, Ohtaki M, Nagao M, et al: Osteoprotegerin prevents development of abdominal aortic aneurysms. PLoS One. 11:e01470882016. View Article : Google Scholar : PubMed/NCBI
28	Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, Kostenuik PJ and Demer LL: Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(−/-) mice. Circulation. 117:411–420. 2008. View Article : Google Scholar : PubMed/NCBI
29	Mäki JM, Räsänen J, Tikkanen H, Sormunen R, Mäkikallio K, Kivirikko KI and Soininen R: Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation. 106:2503–2509. 2002. View Article : Google Scholar : PubMed/NCBI
30	Callegari A, Coons ML, Ricks JL, Rosenfeld ME and Scatena M: Increased calcification in osteoprotegerin-deficient smooth muscle cells: Dependence on receptor activator of NF-κB ligand and interleukin 6. J Vasc Res. 51:118–131. 2014. View Article : Google Scholar : PubMed/NCBI
31	Olesen P, Ledet T and Rasmussen LM: Arterial osteoprotegerin: Increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia. 48:561–568. 2005. View Article : Google Scholar : PubMed/NCBI
32	Zhang J, Fu M, Myles D, Zhu X, Du J, Cao X and Chen YE: PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett. 521:180–184. 2002. View Article : Google Scholar : PubMed/NCBI